Meeting
2020 ASCO Virtual Scientific Program
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
Authors
Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Danny Rischin , Matthew G. Fury , Israel Lowy , Elizabeth Stankevich , Hyunsil Han , Sandro Porceddu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03969004
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS10084)
DOI
10.1200/JCO.2020.38.15_suppl.TPS10084
Abstract #
TPS10084
Poster Bd #
433
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin
Poster
2019 ASCO Annual Meeting
KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma.
First Author: Jessica Lyn Geiger
Poster
2023 ASCO Annual Meeting
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
First Author: Yi Zhang
Poster
2021 ASCO Annual Meeting
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
First Author: Toon Van Gorp